Solution of early immune-response and development of new strategies of antibody-mediated rejection in kidney transplantation.

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462464
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: Omoto Kazuya 東京女子医科大学, 医学部, 准講師 (90343558)
• Co-Investigator(Renkei-kenkyūsha): ABE Ryo 東京理科大学, 生命科学研究所, 教授 (20159453)
• Research Collaborator: SAWADA Yugo ; HIRAI Toshihito
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 腎移植 / 抗体関連型拒絶 / 感作 / 抗ドナー抗体 / 調節性T細胞 / BAFF

Outline of Final Research Achievements

Intravenous immunoglobulin (IVIG) has evolved widespread use for treatment of antibody-mediated rejection (AMR). In order to investigate the mechanisms of IVIG and sequential fluctuation of donor-specific antibodies (DSA) titer, we administered high dose IVIG to sensitized recipient rats and measured the DSA-IgG levels sequentially. The levels of DSA-IgG in sensitized rats though IVIG gradually decreased. Then we could evaluate sequential pathological findings related to IVIG. Graft survival in IVIG group was significantly longer than that in PS group, but not in nonsensitized group. Additionally, BAFF serum levels successfully decreased, and significant in vivo increasing of proportion of regulatory T cells were observed in IVIG group. Thus, IVIG monotherapy can suppress the production of DSA-IgG and progress of AMR. However, it is insufficient to obtain complete desensitization, so that combination therapies which are targeting to various memory cells might be required.

Free Research Field

免疫寛容、移植免疫